CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Entero Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Entero Therapeutics Inc
777 Yamato Road, Suite 502
Phone: (561) 589-7020p:561 589-7020 BOCA RATON, FL  33431  United States Ticker: ENTOENTO
Business Summary
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The Company is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The Company is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Interim Chief Executive Officer Richard J.Paolone 34 2/12/2025 2/3/2025
President, Director JackSyage 69 7/17/2024 3/13/2024
Chief Financial Officer AnnaSkowron 3/7/2025 3/7/2025
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ImmunogenX, Inc. 1600 Dove Street Newport Beach CA United States

Business Names
Business Name
AZRX
AzurRx SAS
ENTO
4 additional Business Names available in full report.

General Information
Number of Employees: 2 (As of 12/31/2024)
Outstanding Shares: 4,765,729 (As of 5/15/2025)
Shareholders: 85
Stock Exchange: NASD
Federal Tax Id: 464993860
Email Address: info@azurrx.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, May 23, 2025